Systemic review of safety and efficacy of approved bio similar for management of rheumatoid arthritis

Abstract

Biological medicines have opened up new doors to treat many diseases, which include cancers, autoimmune conditions, diabetes, and so on. Stem-cell and gene therapies, insulin, and monoclonal antibodies are all some of the many instances of biological therapies.Biological Disease-modifying antirheumatic drugs (bDMARDs), such as monoclonal antibodies and receptor Fc-fusion proteins that target the tumor necrosis factor (TNF), are the recent development in treatment for patients with rheumatic conditions.Patients who are inadequate respondents to stand-alone conventional synthetic DMARDs have significant improvement in symptoms and outcomes with bDMARDs in various rheumatic conditions.Despite the betterment of the disease, the higher cost when compared to the conventional DMARDs makes bDMARDs less accessible to underprivileged patients. This inequality in the treatment because of the increased cost is being bridged nowadays with the development of lower-cost agents.This review evaluates the safety and efficacy of the Biosimilars in the treatment of Rheumatoid arthritis.